Opening book details…
Can I read Immune Checkpoint Inhibitor-bullous Pemphigoid Is Characterized by Interleukin-4 and Interleukin-13 Expression and Responds to Dupilumab Treatment on EtoBox?
Immune Checkpoint Inhibitor-bullous Pemphigoid Is Characterized by Interleukin-4 and Interleukin-13 Expression and Responds to Dupilumab Treatment by William D Shipman; Katelyn Singh; Jeffrey M Cohen; Jonathan Leventhal; William Damsky; Mary M Tomayko is a Medicine article available to read on EtoBox.
What is Immune Checkpoint Inhibitor-bullous Pemphigoid Is Characterized by Interleukin-4 and Interleukin-13 Expression and Responds to Dupilumab Treatment about?
Immune check point inhibitor-induced bullous pemphigoid (ICI-BP) is a clinically debilitating immune related adverse event in need of novel therapeutic approaches, as conventional therapy treatment can counteract intended tumor immunity. Here we demonstrate that IL4 and IL13 cytokine expression is elevated in ICI-BP similar to conventional autoimmune bullous pemphigoid and further demonstrate partial and complete disease clearance in four ICI-BP patients with dupilumab. These data indicate that IL-4Ralpha inhibition may be a promising new therapy for ICI-BP.
Who reads Immune Checkpoint Inhibitor-bullous Pemphigoid Is Characterized by Interleukin-4 and Interleukin-13 Expression and Responds to Dupilumab Treatment?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- William D Shipman; Katelyn Singh; Jeffrey M Cohen; Jonathan Leventhal; William Damsky; Mary M Tomayko
- Publisher
- Oxford University Press (OUP)
- Published
- 2023
- Language
- EN
- Field
- Medicine (Health Sciences)